AR and prostate carcinoma: ADT results in the state of BRCAness, a phenotype with treatment susceptibility analogous to that of BRCA dysfunctional cancer, including HR deficiency and increased PARP activation, leading to sensitivity of prostate cancer to PARP inhibition in combination with AR signaling inhibitors in preclinical setting [51].